Phase 1 Study of SIM0689 for Advanced Solid Tumors Initiated by Jiangsu Simcere
A Phase 1 study of SIM0689 is underway to evaluate its safety and early efficacy in adult patients with advanced solid tumors.
Company
Pharmaceutical intelligence for Jiangsu Simcere Pharmaceutical Co., Ltd. with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.